Manuel Litchman (Mustang Bio Inc. (Nasdaq: MBIO))

Litchman, Manuel (Mustang Bio 201704– CEO before Arvinas + Novartis Pharmaceuticals Corp)

	Organisation	Mustang Bio Inc. (Nasdaq: MBIO)
	Former/major organisation	Arvinas Inc. (Nasdaq: ARVN)
	Group	Arvinas (Group)
	Product	gene therapy
	Product 2	PROTAC technology (proteolysis targeting chimeric molecules)

Record changed: 2020-11-07

Picture Berlin Partner Top News New Ariceum Radiopharma Lab 650x200px

More documents for Manuel Litchman

[1] Sirion Biotech GmbH. (10/6/20). "Press Release: Mustang Bio Licenses LentiBOOST Technology from Sirion Biotech for the Development of MB-207 Lentiviral Gene Therapy". Worcester, MA & Martinsried....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)